144
IRUS Total
Downloads
  Altmetric

A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics

File Description SizeFormat 
s41467-020-18130-3.pdfPublished version1.07 MBAdobe PDFView/Open
Title: A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics
Authors: Crone, M
Priestman, M
Ciechonska, M
Jensen, K
Sharp, D
Anand, A
Randell, P
Storch, M
Freemont, P
Item Type: Journal Article
Abstract: The SARS-CoV-2 pandemic has shown how a rapid rise in demand for patient and community sample testing can quickly overwhelm testing capability globally. With most diagnostic infrastructure dependent on specialized instruments, their exclusive reagent supplies quickly become bottlenecks, creating an urgent need for approaches to boost testing capacity. We address this challenge by refocusing the London Biofoundry onto the development of alternative testing pipelines. Here, we present a reagent-agnostic automated SARS-CoV-2 testing platform that can be quickly deployed and scaled. Using an in-house-generated, open-source, MS2-virus-like particle (VLP) SARS-CoV-2 standard, we validate RNA extraction and RT-qPCR workflows as well as two detection assays based on CRISPR-Cas13a and RT-loop-mediated isothermal amplification (RT-LAMP). In collaboration with an NHS diagnostic testing lab, we report the performance of the overall workflow and detection of SARS-CoV-2 in patient samples using RT-qPCR, CRISPR-Cas13a, and RT-LAMP. The validated RNA extraction and RT-qPCR platform has been installed in NHS diagnostic labs, increasing testing capacity by 1000 samples per day.
Issue Date: 8-Sep-2020
Date of Acceptance: 5-Aug-2020
URI: http://hdl.handle.net/10044/1/81660
DOI: 10.1038/s41467-020-18130-3
ISSN: 2041-1723
Publisher: Nature Research
Start Page: 1
End Page: 11
Journal / Book Title: Nature Communications
Volume: 11
Copyright Statement: © The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/ licenses/by/4.0/.
Sponsor/Funder: Engineering & Physical Science Research Council (E
Engineering & Physical Science Research Council (EPSRC)
Biotechnology and Biological Sciences Research Council (BBSRC)
NPL Management Limited
UK DRI Ltd
Funder's Grant Number: RG91264
EP/S001859/1
BB/M025632/1
N/A
'CR & T IMP'
Publication Status: Published
Article Number: 4464
Online Publication Date: 2020-09-08
Appears in Collections:Department of Infectious Diseases
Faculty of Medicine
Imperial College London COVID-19
Department of Brain Sciences



This item is licensed under a Creative Commons License Creative Commons